These in vivo experiments confirmed that suppressing ADAM17 expression increases VE-cadherin expression at the tumor invasion front, thereby mitigating the upregulation of CRC hematogenous metastasis and pre-metastatic niche formation otherwise induced by ADAM17. Here, CDH5 is linked to neoplasm.